Pandemia de COVID-19 y enfermedad renal ¿qué sabemos actualmente?

Palabras clave: falla renal aguda; COVID-19; enfermedades renales; ECA2; nuevo coronavirus 2019; diálisis renal, fallo renal crónico

Resumen

Introducción: La enfermedad renal aguda es una patología relativamente frecuente en pacientes con infección por COVID-19, en especial en el grupo de pacientes que se encuentran críticamente enfermos; los pacientes con enfermedad renal crónica se consideran un grupo de riesgo durante la pandemia debido a la inmunosupresión asociada por lo cual es importante la detección de infección por SARS CoV-2 en estos pacientes además de quienes están en diálisis y pacientes con trasplante renal. Es de suma importancia la identificación de enfermedad renal al ingreso de pacientes con COVID-19 pues se ha demostrado que representa un indicador para valorar supervivencia y pronóstico; varios estudios han establecido que la falla renal aguda se relaciona directamente con peor pronóstico y mortalidad. Debido al impacto positivo en la supervivencia que significa el manejo oportuno de la falla renal en pacientes positivos para COVID-19, Objetivo: presentar la información científica actual sobre la fisiopatología de falla renal en contexto de COVID-19, diagnóstico, tratamiento, estrategias de seguimiento de la función renal durante la hospitalización, manejo de unidades de diálisis, indicación de líquidos intravenosos y manejo de shock en pacientes con enfermedad renal.
Métodos: Se realizó una revisión de la literatura utilizando las bases de datos PubMed, Google Scholar y Embase; los criterios de selección incluían artículos que registraran el abordaje general y específico de complicaciones en el contexto de enfermedad renal, no se usaron filtros en la búsqueda.
Conclusión: la falla renal en el contexto de la infección por COVID-19 representa un aspecto importante a estudiar dentro del desarrollo de la enfermedad y requiere consideraciones especiales para su manejo.

Descargas

La descarga de datos todavía no está disponible.

Referencias

[1] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 2020;2:m1091. doi:10.1136/bmj.m1091.
[2] Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China. Chin Med J (Engl) 2020;2019:1. doi:10.1097/cm9.0000000000000824.
[3] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;0. doi:10.1016/S2213-2600(20)30079-5.
[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5.
[5] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;0. doi:10.1016/j.kint.2020.03.005.
[6] Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID - 19 outbreak : a study based on single-cell transcriptome analysis. Intensive Care Med 2020:2–4. doi:10.1007/s00134-020-06026-1.
[7] Prevention KS of ID and KC for DC. Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020. J Korean Med Sci 2020;35:1–9. doi:10.3346/jkms.2020.35.e132.
[8] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc 2020;323:1061–9. doi:10.1001/jama.2020.1585.
[9] Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020;2019:1–10. doi:10.1007/s11684-020-0767-8.
[10] Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87:281–6. doi:10.1007/s12098-020-03263-6.
[11] Rismanbaf A, Zarei S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. Arch Acad Emerg Med 2020;8:e17.
[12] Valizadeh B, Baradaran A, Mirzazadeh A BL. Coronavirus-nephropathy; renal involvement in COVID-19. J Ren Inj Prev Coronavirus-Nephropathy 2020;9:3–4. doi:10.34172/jrip.2020.18.
[13] Naicker S, Yang C, Hwang S. A summary of the guidelines by the Chinese Society of Nephrology and the Taiwan Society of Nephrology 2020:7–9.
[14] Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 2020. doi:10.1016/j.kint.2020.03.001.
[15] Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003;361:1767–72. doi:10.1016/S0140-6736(03)13412-5.
[16] Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron 2020:1–9. doi:10.1159/000507305.
[17] Xianghong Y, Renhua S, Dechang C. Diagnóstico y tratamiento de la nueva neumonía por coronavirus: no se puede ignorar la lesión renal aguda. Chin Med J (Engl) 2020. doi:10.3760 / cma.j.cn112137-20200229-00520.
[18] Zhang F, Liang Y. The potential risk of kidney vulnerable to novel coronavirus 2019 infection. Am J Physiol Physiol 2020:ajprenal.00085.2020. doi:10.1152/ajprenal.00085.2020.
[19] Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol 2020;430060:1–6. doi:10.1159/000507471.
[20] Kumar A. Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada. JAMA 2009;302:1872. doi:10.1001/jama.2009.1496.
[21] Kong H, Mary Q, Pathology C, Care I. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome K A S HUN F UNG , H ON L OK T ANG , W ING W A Y AN , H ILDA W . H . C HAN , T HOMAS S . T . L AI , 2005;67:698–705.
[22] Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020:1–3. doi:https://doi.org/10.1038/s41581-020-0284-7.
[23] Xianghong Y, Renhua S, Dechang C, Provincial Z, Medicine C, Hospital R. 新型冠状病毒肺炎诊治:急性肾损伤不容忽视. Chin Med J (Engl) 2020;100:4–7. doi:10.3760/cma.j.cn112137-20200229-00520.
[24] Li, Zhen y Wu, Ming y Yao, Jiwei y Guo, Jie y Liao, Xiang y Song, Siji y Li, Jiali y Duan, Guangjie y Zhou, Yuanxiu y Wu, Xiaojun y Zhou, Zhansong y Wang, Taojiao y Hu, Ming y Chen, Xianxiang y Fu, Yu y Lei, Chong y Dong, Hailong y Xu, Chuou y Hu, Yahua y J. Infectious Diseases Caution on Kidney Dysfunctions of COVID-19 Patients. Lancet Infect Dis 2020:1–25.
[25] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Li J, Yao Y, Ge S XG. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020:1–10.
[26] Zhang F LY. Letter to the editor:The potential risk of kidney vulnerable to novel coronavirus 2019 infection. J Physiol Physiol Ren 2020. doi:10.1152 / ajprenal.00085.2020.
[27] Expert team of chinese medical association nephrology branch. Expert consensus on diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection with acute kidney injury. Chinese J Nephrol 2020;36:1–11. doi:10.3760/cma.j.cn441217-20200222-00035.
[28] Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Reports 2020. doi:10.1016/j.ekir.2020.04.001.
[29] Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237.
[30] U.S Food and Drug Administration. FACT SHEET FOR PATIENTS AND PARENT/CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. 2020.
[31] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69. doi:10.1186/1743-422X-2-69.
[32] Dan Z, Sheng-Ming D, Qiang T. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression | Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother 2020:1–4. doi:https://doi.org/10.1093/jac/dkaa114.
[33] Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020. doi:10.1016/j.ijantimicag.2020.105938.
[34] Bo Z, Wei Z, Yang H, Xuelian Y, Yang Y, Dan M, et al. Research progress of chloroquine-associated sever adverse reactions. Advers Drug React J 2020;22:E008–E008. doi:10.3760/CMA.J.CN114015-20200222-00148.
[35] Saavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio 2020;24:1. doi:10.22354/in.v24i3.851.
[36] Food and Drug Administration. FDA LABEL PLAQUENIL ® HYDROXYCHLOROQUINE SULFATE TABLETS, USP DESCRIPTION. 2017.
[37] Seyffart G. Drug Dosage in Renal Insufficiency . Springer; 1991.
[38] Ashley C, Dunleavy A. The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioner. 5th ed. CRC Press; 2018.
[39] University of California. Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis. HIV Insite 2017.
[40] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020:NEJMoa2001282. doi:10.1056/NEJMoa2001282.
[41] Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res 2020:1–8. doi:10.1007/s00011-020-01342-0.
[42] Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into korea from wuhan, china: Implication for infection prevention and control measures. J Korean Med Sci 2020;35. doi:10.3346/jkms.2020.35.e61.
[43] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71. doi:10.1038/s41422-020-0282-0.
[44] Cao Y, Deng Q, Dai S. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 2020:101647. doi:10.1016/j.tmaid.2020.101647.
[45] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382:929–36. doi:10.1056/NEJMoa2001191.
[46] Human Medicines Division. Summary on compassionate use Remdesivir . 2020.
[47] China-Japan Friendship Hospital, Cao B, Wang Yeming. Severe 2019-nCoV Remdesivir RCT . NIH US Natl Libr Med Clin 2020.
[48] Cao B, Wang Y. Mild/Moderate 2019-nCoV Remdesivir RCT . NIH US Natl Libr Med Clin 2020.
[49] Gilead Clinical Study Information Center. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment . NIH US Natl Libr Med Clin 2020.
[50] Gilead Clinical Study Information Center. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Severe Coronavirus Disease (COVID-19) . NIH US Natl Libr Med Clin 2020.
[51] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020. doi:10.1016/j.ijantimicag.2020.105949.
[52] Ministerio de Salud y Protección Social de Colombia. Guía de Práctica Clínica para el diagnóstico y tratamiento de la Enfermedad Renal Crónica . 2016.
[53] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Who 2020:1–21.
[54] Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 2018;197:757–67. doi:10.1164/rccm.201706-1172OC.
[55] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv 2020:1–12.
[56] Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. BioRxiv 2020:4.08.029769. doi:10.1101/2020.04.08.029769.
[57] National Kidney Disease Professional Medical Quality Management and Control Center, China Medical Promotion Association Blood Purification Treatment and Engineering Technology Branch ABPTPC. 新型冠状病毒肺炎救治中 CRRT 应用的专家意见 2020:4–7.
[58] Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic : preparing for extracorporeal organ support in intensive care. Lancet Respir 2019;8:240–1. doi:10.1016/S2213-2600(20)30060-6.
[59] Naicker S, Yang C, Hwang S, Liu B, Chen J J V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 2020. doi:10.1016/j.kint.2020.03.001.
[60] Choi Y, Hoon D, Oh J, Wee J, Jang T, Choi S PK. Renal replacement therapy is independently associated with a lower risk of death in patients with severe acute kidney injury treated with targeted temperature management after out-of- hospital cardiac arrest. Crit Care 2020;24:115.
[61] Ghani RA, Zainudin S, Ctkong N, Fauzi A, Rahman A, Rozaidi S, et al. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration SUMMARY : Nephrol 2006; 2006;11:386–93. doi:10.1111/j.1440-1797.2006.00600.x.
[62] American Society of Nephrology. Recommendations on the Care of Hospitalized Patients with Covid-19 and Kidney Failure Requiring Renal Replacement Therapy n.d.
[63] Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle. Am J Kidney Dis 2020.
[64] CDC: National Center for Immunization and Respiratory Diseases (NCIRD) Division of Viral Diseases. Interim Additional Guidance for Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed COVID-19 in Outpatient Hemodialysis Facilities | CDC n.d.
[65] De Sequera Ortiz P, Quiroga Gili B, de Arriba de la Fuente G, Macía Heras M, Salgueira Lazo M, del Pino y Pino MD. Protocolo de actuación ante la epidemia de enfermedad por coronavirus en los pacientes de diálisis y trasplantados renales. Nefrología 2020. doi:10.1016/j.nefro.2020.03.001.
[66] Mercedes JA, Franco A, Gonz F, Guirado L, Jim C, Rodr A, et al. Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal. J Pre-Proof 2020;2. doi:10.1016/j.nefro.2020.03.002.
[67] Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. COVID-19 in post-transplantation patients- report of two cases. Am J Transplant 2020. doi:10.1111/ajt.15896.
[68] Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, et al. Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression. Am J Transplant 2020:1–5. doi:10.1111/ajt.15869.
[69] Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int 2020. doi:10.1016/j.kint.2020.03.018.
[70] Waleed Alhazzani A, Hylander Møller M, Arabi YM, Loeb M, Ng Gong M, Fan E, et al. Intensive Care Medicine GUIDELINES Un-edited accepted proof* Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) n.d. doi:10.1007/s00134-020-06022-5.
[71] Mart A, Ja BM, Jm E, Mn P. Antequera Martín AM, Barea Mendoza JA, Muriel A, Sáez I, Chico-Fernández M, Estrada-Lorenzo JM, Plana MN. Cochrane Database Syst Rev 2019. doi:10.1002/14651858.CD012247.pub2.www.cochranelibrary.com.
[72] Meyhoff TS, Møller MH, Hjortrup PB, Cronhjort M, Perner A, Wetterslev J. Lower vs Higher Fluid Volumes During Initial Management of Sepsis. Chest 2020. doi:10.1016/j.chest.2019.11.050.
[73] Silversides JA, Major E, Ferguson AJ, Mann EE, McAuley DF, Marshall JC, Blackwood B FE. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and metaanalysis. Intensive Care Med 2017;43:155–70.
[74] Ayala GU, Patricia D, Yucra C. Falla Renal Aguda Por Sepsis. Rev Med La Paz 2019;25:25.
[75] Lewis S, Pritchard M, Evans D, Butler A, Alderson P, Smith A, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Cochrane Database Syst Rev 2018:1–182. doi:10.1002/14651858.CD000567.pub7.www.cochranelibrary.com.
[76] Aguilar FG. Manejo de fluidos intravenosos. Med Crit 2018;32:100–7.
[77] Moller MH, Claudius C, Junttila E, Haney M, Oscarsson-Tibblin A, Haavind A PA. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. Acta Anaesthesiol Scand 2016;60:1347–66.
[78] Havel C, Arrich J, Losert H, Gamper G, Müllner M, Herkner H. Vasopressors for hypotensive shock ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Library (Lond) 2011. doi:10.1002/14651858.CD003709.pub4.www.cochranelibrary.com.
[79] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis 2020. doi:10.1093/cid/ciaa199.
[80] Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27:171–8. doi:10.1016/j.tmrv.2013.05.004.
Publicado
2020-05-08
Cómo citar
1.
Caicedo Mesa A, Méndez Fandiño YR, Larrotta Salamanca LX, Díaz Lache LL, Forero Alvarado MJ, Cortés Motta HF, Acosta Costilla Álvaro F. Pandemia de COVID-19 y enfermedad renal ¿qué sabemos actualmente?. Rev. Colomb. Nefrol. [Internet]. 8 de mayo de 2020 [citado 4 de junio de 2020];7(Supl 2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/438
Sección
Artículo de revisión